文献速递前列腺癌

非洲加勒比男性低危前列腺癌主动监测的前瞻性研究结果

Active Surveillance for Favorable Risk Prostate Cancer in African Caribbean Men: Results of a Prospective Study.
PubMed 文献 · J Urol · 2016-12-18

在瓜德罗普对234例低危或有利中危前列腺癌患者进行单中心前瞻性队列研究,中位随访4年。30个月、5年和10年总生存率分别为99.5%、98.5%和90.7%,疾病特异性生存率均为100%。年龄(HR 0.96)和前列腺特异性抗原密度(HR 1.52)是主动监测终止的独立预测因素。

要点

  • 非洲加勒比低危或有利中危前列腺癌患者主动监测10年疾病特异性生存率100%。
  • 30个月、5年和10年仍处于主动监测未治疗的比例分别为72.7%、52.6%和40.4%。
  • 年龄(HR 0.96)和PSA密度(HR 1.52)是主动监测终止的独立预测因素。

核心结论

  • 主动监测对经过高度选择的非洲加勒比患者是安全且有益的,对低危和有利中危患者似乎是可行的,PSA密度可能有助于更好地选择这些患者。

研究设计与样本

  • 2005年至2016年在法属西印度群岛瓜德罗普进行的单中心前瞻性队列研究,纳入234例低危(PSA≤10 ng/ml且Gleason评分≤6)或有利中危(PSA 10-20 ng/ml、Gleason评分≤3+4且预期寿命<10年)前列腺癌患者,中位年龄64岁,中位随访4年(IQR 2.3-5.5)。

主要发现

  • 30个月、5年和10年总生存率分别为99.5%、98.5%和90.7%。
  • 30个月、5年和10年疾病特异性生存率均为100%。
  • 30个月、5年和10年仍处于主动监测未治疗的比例分别为72.7%、52.6%和40.4%。
  • 年龄(每增加1岁HR 0.96,95%CI 0.93-0.99)和PSA密度(每增加0.1 ng/ml HR 1.52,95%CI 1.20-1.89)是主动监测终止的独立预测因素。

关键数值与推荐

  • 低危定义:PSA≤10 ng/ml且Gleason评分≤6;有利中危定义:PSA 10-20 ng/ml、Gleason评分≤3+4且预期寿命<10年。
  • 治疗推荐指征:分级进展、肿瘤体积增大、前列腺癌倍增时间<36个月或患者意愿。

临床怎么用

  • 作者认为主动监测对经过高度选择的非洲加勒比低危和有利中危前列腺癌患者似乎是安全且有益的。
  • 作者认为PSA密度可能有助于更好地选择适合主动监测的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Active surveillance is a treatment option for favorable risk prostate cancer. However, data are missing on populations of African descent. We evaluated the safety and benefit of active surveillance in an African Caribbean cohort with favorable risk prostate cancer. MATERIALS AND METHODS: Between 2005 and 2016, a single center, prospective cohort study was performed in Guadeloupe, French West Indies, including patients on active surveillance who had low risk prostate cancer (prostate specific antigen 10 ng/ml or less and Gleason score 6 or less) or favorable intermediate risk prostate cancer (prostate specific antigen 10 to 20 ng/ml, Gleason score 3 + 4 or less and life expectancy less than 10 years). Treatment was recommended in case of grade progression, increased tumor volume, prostate cancer doubling time less than 36 months or patient wish. Overall survival, disease specific survival and duration of active surveillance were calculated with the Kaplan-Meier method. Multivariate analysis was performed using the Cox proportional hazards model to identify predictors of active surveillance termination. RESULTS: A total of 234 patients with a median age of 64 years were enrolled in study. Median followup was 4 years (IQR 2.3-5.5). Overall survival at 30 months, 5 years and 10 years was 99.5%, 98.5% and 90.7%, respectively. Disease specific survival at 30 months, and 5 and 10 years was 100%. At 30 months, 5 years and 10 years 72.7%, 52.6% and 40.4% of patients, respectively, remained untreated and on active surveillance. Age (HR 0.96 per additional year, 95% CI 0.93-0.99) and prostate specific antigen density (HR 1.52 per additional 0.1 ng/ml, 95% CI 1.20-1.89) were found to be independent predictors of active surveillance termination. CONCLUSIONS: Active surveillance is safe and beneficial for highly selected African Caribbean patients. It seems to be feasible for patients at low risk and intermediate favorable risk. Prostate specific antigen density could help better select these patients.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Meunier ME, Eyraud R, Sénéchal C, et al. Active Surveillance for Favorable Risk Prostate Cancer in African Caribbean Men: Results of a Prospective Study. J Urol. 2016. PMID: 27993665. doi:10.1016/j.juro.2016.12.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。